Seagen, a wholly owned subsidiary of Pfizer
Registry sponsor category
Industry
- Other names
- Seagen, a wholly owned subsidiary of Pfizer
- Company name
- Seagen, a wholly owned subsidiary of Pfizer
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (31)
- A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
- A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
- A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
- A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
- A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
- A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- A Study of SGN-MesoC2 in Advanced Solid Tumors
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
- A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer